{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:24:48Z","timestamp":1783689888994,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"DOI":"10.1007\/s15010-026-02822-x","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:04:42Z","timestamp":1783688682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of extensively drug-resistant tuberculosis and drug resistance patterns in Asia and Africa (2000\u20132025): systematic review and meta-analysis"],"prefix":"10.1007","author":[{"given":"Dharshiga","family":"Ravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Yusnoraini","family":"Yusof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Zulkifli","family":"Salleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Yean","family":"Yean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarahani","family":"Harun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Siti Hanifah Nik","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"9732","key":"2822_CR1","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/S0140-6736(10)60554-5","volume":"375","author":"BJ Marais","year":"2013","unstructured":"Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. The Lancet. 2013;375(9732):2179\u201391.","journal-title":"The Lancet"},{"key":"2822_CR2","unstructured":"World Health Organization. (2023). Global tuberculosis report 2023. World Health Organization."},{"key":"2822_CR3","doi-asserted-by":"crossref","unstructured":"Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., Murray, M., Furin, J., ... & Warren, R. M. (2017). The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet Respiratory Medicine, 5(4), 291\u2013360.","DOI":"10.1016\/S2213-2600(17)30079-6"},{"key":"2822_CR4","first-page":"1","volume":"32","author":"C Xu","year":"2023","unstructured":"Xu C, Wang J, Zhang Y, Liu J, Sun Y. Prevalence and resistance patterns of extensively drug-resistant tuberculosis: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2023;32:1\u20139.","journal-title":"J Glob Antimicrob Resist"},{"key":"2822_CR5","volume":"11","author":"M Yuan","year":"2023","unstructured":"Yuan M, Pang Y, Li Y, Cao Y, Lu W. Global burden and trends of extensively drug-resistant tuberculosis from 2010 to 2019: a modeling study. Front Public Health. 2023;11:1177085.","journal-title":"Front Public Health"},{"key":"2822_CR6","volume":"14","author":"R Li","year":"2024","unstructured":"Li R, Zhang Q, Sun Q, Yu J, Li Y. Trends in multidrug-resistant and extensively drug-resistant tuberculosis in China: a meta-analysis of 88,000 TB cases. Sci Rep. 2024;14:3894.","journal-title":"Sci Rep"},{"issue":"6","key":"2822_CR7","volume":"15","author":"AA Gizaw","year":"2020","unstructured":"Gizaw AA, Wake GE, Ayele AA. Drug-resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2020;15(6):e0235003.","journal-title":"PLoS ONE"},{"issue":"8","key":"2822_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.5588\/ijtld.15.0123","volume":"19","author":"P Isaakidis","year":"2015","unstructured":"Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969\u201378.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"2822_CR9","volume":"57","author":"MR Farhat","year":"2019","unstructured":"Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, et al. Gyrase mutations are associated with variable levels of fluoroquinolone resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2019;57(10):e00389-19.","journal-title":"J Clin Microbiol"},{"key":"2822_CR10","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoff mann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: An updated guideline for reporting systematicreviews.BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"2822_CR11","doi-asserted-by":"crossref","unstructured":"Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, et al. National surveyof drug-resistant tuberculosis in China. The New England Journal of Medicine. 2012;366(23):2161\u20132170.","DOI":"10.1056\/NEJMoa1108789"},{"issue":"10","key":"2822_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","volume":"16","author":"M Zignol","year":"2016","unstructured":"Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185\u201392.","journal-title":"Lancet Infect Dis"},{"key":"2822_CR13","doi-asserted-by":"crossref","unstructured":"Silva DR, Mu\u00f1oz-Torrico M, Duarte R, Galv\u00e3o T, Bonini EH, Arbex FF, Arbex MA, Augusto VM, Rabahi M.F, Mello FCQ. Risk factors for tuberculosis: Diabetes, smoking, alcohol use, and the use of other drugs. Journal of Bras Pneumology. 2020;44(2):e20180011.","DOI":"10.1590\/s1806-37562017000000443"},{"key":"2822_CR14","doi-asserted-by":"crossref","unstructured":"Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. ClinicalInfectious Diseases. 2012;54(4):579\u201381.","DOI":"10.1093\/cid\/cir889"},{"issue":"5","key":"2822_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-002418","volume":"5","author":"SR Atre","year":"2020","unstructured":"Atre SR, Douthwaite S, Khatri R. Why the WHO recommended shorter regimen for MDR-TB may not be universally applicable. BMJ Glob Health. 2020;5(5):e002418. https:\/\/doi.org\/10.1136\/bmjgh-2020-002418.","journal-title":"BMJ Glob Health"},{"key":"2822_CR16","unstructured":"Ministry of Health and Family Welfare. (2024). National guidelines for the programmatic management of drug-resistant tuberculosis in India. Government of India."},{"key":"2822_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1186\/s12889-017-4779-5","volume":"17","author":"BMC Public Health","year":"2017","unstructured":"BMC Public Health. Prevalence of drug-resistant pulmonary tuberculosis in India: Systematic review and meta-analysis. BMC Public Health. 2017;17:817. https:\/\/doi.org\/10.1186\/s12889-017-4779-5.","journal-title":"BMC Public Health"},{"issue":"4","key":"2822_CR18","first-page":"512","volume":"66","author":"PubMed","year":"2019","unstructured":"PubMed. Sociodemographic profile of MDR-TB and XDR-TB patients: a study from North India. Indian J Tuberc. 2019;66(4):512\u20139.","journal-title":"Indian J Tuberc"},{"issue":"5","key":"2822_CR19","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.1093\/cid\/ciab130","volume":"73","author":"R Li","year":"2021","unstructured":"Li R, Ruan Y, Sun Q, Chen M, Dou H, Liu Z, et al. Evolution of drug-resistant tuberculosis in China: a nationwide survey. Clin Infect Dis. 2021;73(5):e1184\u201391. https:\/\/doi.org\/10.1093\/cid\/ciab130.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2822_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cmi.2019.09.010","volume":"26","author":"S Tang","year":"2020","unstructured":"Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, et al. Efficacy and safety of bedaquiline-containing regimens in the treatment of multidrug- and extensively drug-resistant tuberculosis patients in China: a multicentre study. Clin Microbiol Infect. 2020;26(3):372\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2019.09.010.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2822_CR21","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/jac\/dkv150","volume":"70","author":"S Zhang","year":"2015","unstructured":"Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2015;70(9):2507\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2822_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.00035114","volume":"45","author":"X Zhang","year":"2015","unstructured":"Zhang X, Falzon D, Jia H, et al. Effectiveness and safety of linezolid in treating multidrug-resistant and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2015;45(1):161\u201373. https:\/\/doi.org\/10.1183\/09031936.00035114.","journal-title":"Eur Respir J"},{"issue":"4","key":"2822_CR23","doi-asserted-by":"publisher","first-page":"e01723","DOI":"10.1128\/jcm.01723-23","volume":"62","author":"Q Liu","year":"2024","unstructured":"Liu Q, Chen C, Guo J, et al. Diagnostic accuracy of the Xpert MTB\/XDR assay for detection of second-line drug resistance in Mycobacterium tuberculosis isolates in China. J Clin Microbiol. 2024;62(4):e01723-e1823. https:\/\/doi.org\/10.1128\/jcm.01723-23.","journal-title":"J Clin Microbiol"},{"issue":"23","key":"2822_CR24","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa1108789","volume":"366","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2013;366(23):2161\u201370. https:\/\/doi.org\/10.1056\/NEJMoa1108789.","journal-title":"N Engl J Med"},{"issue":"1","key":"2822_CR25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12879-020-05373-9","volume":"20","author":"L Wang","year":"2020","unstructured":"Wang L, Zhang H, Ruan Y, et al. Characteristics and treatment outcomes of patients with drug-resistant tuberculosis in Zhejiang Province China. BMC Infect Dis. 2020;20(1):640. https:\/\/doi.org\/10.1186\/s12879-020-05373-9.","journal-title":"BMC Infect Dis"},{"key":"2822_CR26","unstructured":"Mugwagwa T, Murewanhema G, Dzinamarira T, Chitungo I, Musuka G. Tuberculosis in Africa in the eraof antimicrobial resistance: A systematic review. Tropical Medicine and Infectious Disease. 2022;7(8):176."},{"key":"2822_CR27","doi-asserted-by":"crossref","unstructured":"Ismail N, Mvusi L, Nanoo, A, Dreyer A, Omar S, Babatunde S, Molebatsi T, van der Walt M, Stevens W. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: A national and sub-nationalcross-sectional survey. The Lancet Infectious Diseases; 2018:18(7):779\u201387.","DOI":"10.1016\/S1473-3099(18)30222-6"},{"key":"2822_CR28","doi-asserted-by":"publisher","unstructured":"Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis. The Lancet. 2010; 375(9728):1830\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(10)60410-2","DOI":"10.1016\/S0140-6736(10)60410-2"},{"key":"2822_CR29","doi-asserted-by":"crossref","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, et al. Global burden of 369 diseases and injuries in 204 countries and territories,1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019.The Lancet. 2020;396(10258):1204\u20131222.","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"2822_CR30","doi-asserted-by":"publisher","unstructured":"Dalton T, Cegielski P, Akksilp S, Asencios L, Caoili JC, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, et al. (2012). Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study. The Lancet. 2012; 380 (9851):1406\u201317 https:\/\/doi.org\/10.1016\/S0140-6736(12)60734-X","DOI":"10.1016\/S0140-6736(12)60734-X"},{"issue":"3","key":"2822_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120470","volume":"10","author":"E Avalos","year":"2015","unstructured":"Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Rodwell T. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS ONE. 2015;10(3):e0120470. https:\/\/doi.org\/10.1371\/journal.pone.0120470.","journal-title":"PLoS ONE"},{"key":"2822_CR32","doi-asserted-by":"crossref","unstructured":"P\u00e1sca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, Riccardi G. Rv2686c-Rv2687c-Rv2688c,an ABC fl uoroquinolone effl ux pump in Mycobacterium tuberculosis.Antimicrobial Agents and Chemotherapy. 2004;48(8):3175\u201378.","DOI":"10.1128\/AAC.48.8.3175-3178.2004"},{"key":"2822_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MGM2-0014-2013","author":"C Vilch\u00e8ze","year":"2014","unstructured":"Vilch\u00e8ze C, Jacobs WR. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr. 2014. https:\/\/doi.org\/10.1128\/microbiolspec.MGM2-0014-2013.","journal-title":"Microbiol Spectr"},{"issue":"5","key":"2822_CR34","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1128\/AAC.06288-11","volume":"56","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. Antimicrob Agents Chemother. 2013;56(5):2223\u201330. https:\/\/doi.org\/10.1128\/AAC.06288-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2822_CR35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","volume":"104","author":"EA Campbell","year":"2001","unstructured":"Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104(6):901\u201312. https:\/\/doi.org\/10.1016\/S0092-8674(01)00286-0.","journal-title":"Cell"},{"issue":"8846","key":"2822_CR36","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","volume":"341","author":"A Telenti","year":"1993","unstructured":"Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647\u201350. https:\/\/doi.org\/10.1016\/0140-6736(93)90417-F.","journal-title":"Lancet"},{"key":"2822_CR37","unstructured":"World Health Organization.(2022).WHO consolidated guidelines on tuberculosis: Module 4: Treatment \u2013 Tuberculosiscare and support. World Health Organization."},{"issue":"3","key":"2822_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3201\/eid1303.061400","volume":"13","author":"NS Shah","year":"2017","unstructured":"Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Mart\u00edn-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2017;13(3):380\u20137.","journal-title":"Emerg Infect Dis"},{"key":"2822_CR39","doi-asserted-by":"publisher","unstructured":"Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, et al. Evolution of extensively drug-resistant tuberculosis over four decades: Whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLoS Medicine. 2015;12(9):e1001880. https:\/\/doi.org\/10.1371\/journal.pmed.1001880","DOI":"10.1371\/journal.pmed.1001880"},{"issue":"8","key":"2822_CR40","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1473-3099(19)30307-X","volume":"19","author":"GM Knight","year":"2019","unstructured":"Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019;19(8):903\u201312.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"2822_CR41","first-page":"1013","volume":"22","author":"M Loveday","year":"2018","unstructured":"Loveday M, Wallengren K, Voce A, Margot B, Reddy T, Brust JCM. MDR-TB patients in KwaZulu-Natal, South Africa: cost and resource use. Int J Tuberc Lung Dis. 2018;22(9):1013\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"2822_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102135","volume":"9","author":"K Andries","year":"2014","unstructured":"Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS ONE. 2014;9(7):e102135. https:\/\/doi.org\/10.1371\/journal.pone.0102135.","journal-title":"PLoS ONE"},{"key":"2822_CR43","doi-asserted-by":"crossref","unstructured":"Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., ... & Spigelman, M. (2020). Treatment of highly drug-resistant pulmonary tuberculosis. New England Journal of Medicine, 382(10), 893\u2013902.","DOI":"10.1056\/NEJMoa1901814"},{"issue":"1","key":"2822_CR44","first-page":"1901195","volume":"55","author":"G Ferlazzo","year":"2020","unstructured":"Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Khogali M, Varaine F, et al. Early safety and efficacy of the combination of bedaquiline and linezolid for the treatment of XDR-TB. Eur Respir J. 2020;55(1):1901195.","journal-title":"Eur Respir J"},{"issue":"5","key":"2822_CR45","volume":"64","author":"D Cadosch","year":"2020","unstructured":"Cadosch D, B\u00f6ttger EC, Brandis G. Mutations in rrl and rplC as molecular markers for linezolid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020;64(5):e01191-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"2822_CR46","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wu X, Zhao X, Wang S, Yang J, Sun Z. Emergence of resistance to linezolid and bedaquiline in MDR-TB: a systematic review and meta-analysis. Front Microbiol. 2021;12:684318.","journal-title":"Front Microbiol"},{"issue":"5","key":"2822_CR47","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/AAC.00037-14","volume":"58","author":"RC Hartkoorn","year":"2014","unstructured":"Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(5):2979\u201381. https:\/\/doi.org\/10.1128\/AAC.00037-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2822_CR48","doi-asserted-by":"publisher","first-page":"e00239","DOI":"10.1128\/AAC.00239-17","volume":"61","author":"J Xu","year":"2017","unstructured":"Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(6):e00239-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"2822_CR49","volume":"10","author":"AM Cabibbe","year":"2021","unstructured":"Cabibbe AM, Spitaleri A, Battaglia S, Colman RE, Suresh A, Uplekar S, et al. Genomic epidemiology of bedaquiline resistance in Mycobacterium tuberculosis. Elife. 2021;10:e64717.","journal-title":"Elife"},{"issue":"4","key":"2822_CR50","first-page":"993","volume":"75","author":"DV Zimenkov","year":"2020","unstructured":"Zimenkov DV, Borisov SE, Poteiko PI, Antonova EY, Isaeva YD, Dovgalyuk IF, et al. Detection of bedaquiline\/clofazimine resistance in Mycobacterium tuberculosis isolates from Russian patients with MDR\/XDR-TB using whole genome sequencing. J Antimicrob Chemother. 2020;75(4):993\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2822_CR51","unstructured":"World Health Organization. (2023). Global tuberculosis report 2023. Retrieved from https:\/\/www.who.int\/publications\/i\/item\/9789240077666"},{"issue":"9","key":"2822_CR52","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2217\/fmb.11.84","volume":"6","author":"SD Lawn","year":"2011","unstructured":"Lawn SD, Nicol MP. Xpert\u00ae MTB\/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6(9):1067\u201382. https:\/\/doi.org\/10.2217\/fmb.11.84.","journal-title":"Future Microbiol"},{"key":"2822_CR53","unstructured":"Ministry of Health and Family Welfare, Government of India. (2024). National guidelines for management of drug-resistant tuberculosis. National TB Elimination Programme. Retrieved from https:\/\/tbcindia.mohfw.gov.in\/wp-content\/uploads\/2025\/01\/National-Guidelines-for-Management-of-DR-TB_Final-website.pdf"},{"issue":"9","key":"2822_CR54","volume":"15","author":"JE Phelan","year":"2019","unstructured":"Phelan JE, Lim DR, Mitarai S, Hibberd ML. Integrating whole-genome sequencing within the National TB Control Programme: lessons from the UK and South Korea. PLoS Pathog. 2019;15(9):e1008235.","journal-title":"PLoS Pathog"},{"issue":"2","key":"2822_CR55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijtb.2021.02.008","volume":"68","author":"R Singla","year":"2021","unstructured":"Singla R, Singla N, Jaiswal A, Sethi P. A study of outcomes of MDR and XDR-TB patients in India treated under the Revised National Tuberculosis Control Programme. Indian J Tuberc. 2021;68(2):135\u201341.","journal-title":"Indian J Tuberc"},{"key":"2822_CR56","doi-asserted-by":"publisher","unstructured":"Bastos ML, Hussain H, Weyer K, Leimane V, Yew WW, Menzies D, Pai M. Treatment outcomes ofpatients with multidrug-resistant and extensively drug-resistant tuberculosis according to HIV status: A systematicreview and meta-analysis. Clinical Infectious Diseases. 2014; 59(3):347\u201361 https:\/\/doi.org\/10.1093\/cid\/ciu319","DOI":"10.1093\/cid\/ciu319"},{"key":"2822_CR57","unstructured":"Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, Gupta A, Vohra V. Seven-year DOTS-Plus pilot experience in India: Results, constraints and issues. The International Journal of Tuberculosis and LungDisease. 2019;13(8):976\u201381."}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02822-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:04:50Z","timestamp":1783688690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02822-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":57,"alternative-id":["2822"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02822-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}